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Abstract 
Objectives
Congenital hypothyroidism (CH) is one of the most common causes of mental 
retardation in children. We investigated the developmental status of children with 
CH screened by Ages & Stages Questionnaires (ASQ) measurement scores.
Materials & Methods
In this retrospective study, neurodevelopmental status of 78 children diagnosed with 
CH followed up at the Outpatient Pediatric Endocrinology Clinic of Besat Hospital, 
Hamadan, Iran from May 2006 to Mar 2013, was evaluated by ASQ method. Data on 
age, sex, birth weight, birth length, head circumference, residency location, parental 
education level, primary venous TSH and T4 levels, age at diagnosis, treatment start 
age and initial levothyroxine dosage were extracted from medical records. Data were 
analyzed using statistical software SPSS. P-value less than 0.05 was considered 
statistically significant.
Results
Of the 78 patients, 34 (43.6%) were female, 32 (41%) had developmental disorder, 
and 56 (71.8%) were living in urban areas. Types of developmental impairments 
included: global motor delay in 13 (40.6%) patients, problem-solving in 11 (34.3%), 
impaired communication skills in 5 (15.6%), impaired fine motor skills in 2 (6.2%), 
and impairment of personal social skills in 1 (3.1%). The average ages for diagnosis 
and treatment were 25.65 days in patients with developmental impairment and 17.99 
days in those without developmental delay. ASQ results showed significant statistical 
correlation with initial dose of levothyroxine (P=0.017), age of hypothyroidism 
diagnosis (P=0.002) and age of treatment initiation (P=0.018).
Conclusion
Early diagnosis and treatment along with initial levothyroxine dose were most 
important factors of ASQ scores of children with CH. Higher dose of the levothyroxine 
is required at onset.
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Introduction
“Congenital hypothyroidism has been introduced 
as one of the most common preventable causes 
of mental retardation which occurs in 1/3000 
neonates” (1). Early identification and treatment 
within 2 wkof age can maintain normal cognitive 
development (2, 3). 
CH can be classified into permanent and transient 
types. Permanent CH can occur because of thyroid 
mal-development (ectopic, hypoplasia, and 
agenesis), an inborn error of thyroid metabolism, 
and central hypothyroidism. Whereas the 
transient type of the disease is attributable to the 
transplacental passage of maternal anti-thyroidal 
medication, maternal thyrotropin receptor blocking 
antibody (TRB-Ab), gene mutation, or iodine 
deficiency (4-7). 
Neurodevelopmental outcome is inversely related 
to the age of diagnosis and treatment of congenital 
hypothyroidism (2). The main objective treatment 
of hypothyroidism is to maintain normal growth 
and neurodevelopment of affected children. 
Therefore, close follow up and clinical evaluation 
along with frequent measurements of serum T4 
and thyroid stimulating hormone (TSH) should be 
performed every few months during the first three 
years of life. 
The physical growth outcome can be evaluated 
by growth chart (8) and neurodevelopment can be 
assessed by a wide variety of tests in toddler and 
preschool-aged child.
 Ages & Stages Questionnaires (ASQ) includes 
developmental screening tests that can help parents 
check their child’s development (9, 10). ASQ so far 
has been translated into many different languages 
and also recognized as a valid and strong tool 
for assessing and screening developmental status 
of children (11). This questionnaire has been 
translated into Persian in order to adapt it to the 
Iranian population. 
Screening programs of congenital hypothyroidism 
dramatically improved the neuropsychological 
outcome in affected children. However, mild 
impairments in neurocognitive function and 
intellectual sequel have been reported in some 
studies of early-treated CH children particularly in 
those with marked retardation of bone age and/or a 
low circulating thyroxin before treatment (12-15). 
We aimed to screen the developmental skills of 3 to 
5 yr old children with congenital hypothyroidism 
detected by neonatal screening program in our 
region. 
Material & Methods
Neonatal screening for congenital hypothyroidism 
was introduced in Iran in May 2005. This cross-
sectional case study was conducted on children 
diagnosed with congenital hypothyroidism 
followed up in Pediatric Endocrinology Clinic of 
Besat Hospital, a tertiary care center in Hamadan, 
Iran, from May 2006 to Mar 2013. The study 
enrollment started in Mar 2013 and was carried out 
for two years. 
ELISA was method of screening to measure TSH 
on filter paper at day 3-7 of birth. Venous blood for 
total T4/ free T4 and TSH was obtained to confirm 
the diagnosis for those with abnormal result 
(TSH>5 mIU/L). Electrochemiluminescence was 
used to measure Total T4 and TSH.
 Criteria for patient recruitment were children 
diagnosed with CH (T4 < 6.5 µg/dL and thyroid-
stimulating hormone (TSH)> 10 mIU/mL after one 
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month of age) (7) followed up at the outpatient 
Pediatric Endocrinology Clinic of Besat Hospital, 
Hamadan, Iran
Data on age, sex, birth weight, birth length, head 
circumference, location of residence, parental 
education level, primary venous TSH and T4 
levels, diagnosis age, age of initiation of treatment, 
initial levothyroxine (L-thyroxin or LT4) dosage, 
mean TSH level at first year and first three years 
after treatment start and number of annual visits 
were extracted from medical records. Congenital 
hypothyroidism cases were eligible for participation 
in this work if they had been treated with LT4 and 
were followed up closely in the first three years of 
life. In accordance with guidelines of American 
Academy of Pediatrics, T4 < 6.5 µg/dL and TSH > 
10 mIU/mL after one month of age was considered 
as CH (7). Children were diagnosed as permanent 
CH if they had serum TSH above 10 mIU/L during 
the first three years of treatment or if they needed 
LT4 therapy beyond 3 yr of age (TSH rise > 6 mIU/
ml with temporary discontinuation of LT4 after the 
age of 3 yr (7, 16). 
Those cases lacking necessary data for the current 
work, and cases that did not have regular follow-up 
for the first three years of life were excluded from 
the study. All children at least three years or more 
and with the criteria of the study were assessed by 
ASQ method. The patients were divided into three 
age groups; 3, 4, and 5 yr old. 
Ages & Stages Questionnaire is a developmental 
screening tool to determine whether a child requires 
further and more comprehensive evaluation/
assessment designed for use by early educators and 
health care professionals. It has 20 questionnaires 
that correspond to age intervals from birth to 6 years. 
Each questionnaire contains simple questions for 
parents to answer about activities that their child 
is (or is not) able to do. The answers are assessed 
in five domains including communication, gross 
motor, fine motor, problem-solving and personal 
social skills (9, 10). The questionnaires are scored 
by converting each response to a numerical value: 
Z (most of the time) = 0
V (sometimes) = 5
X (rarely, never) = 10
If a parent identifies an item as a concern (circles to 
far right on form), an extra 5 points are scored for 
that item. Once the total score is calculated, if that 
score is higher than the cut-off score, the screening 
results suggest the child should be referred to 
child development specialist for a developmental 
checkup.
Statistical analysis
The Chi-square test was employed to analyze 
qualitative (categorical) variables expressed as 
ratio and percentages. For analyzing quantitative 
data, their normality of distribution was assessed 
based on mean and standard deviations. In order 
to compare qualitative variables between groups, 
chi-square test, and Fisher’s exact test were used. 
To compare quantitative factors in two groups in 
the case of normality, independent t-test and for 
variables where the distributions of scores differed 
significantly from the normal distribution, Mann-
Whitney U tests were used. All analyses were 
performed with statistical software SPSS ver.16 
(Chicago, IL, USA). A P-value less than 0.05 was 
considered statistically significant. 
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Ethics approval 
The Ethics and Research Committee of Hamadan 
University of Medical Sciences approved the study, 
No: IR.UMSHA.REC.1394.380. Written informed 
consent was obtained from parents of children. 
Results 
Of 78 children, 34 (43.6%) were female, 56 
(71.8%) were living in urban areas, and 22 
(28.2%) were living in rural areas. Demographic 
characteristics of included subjects are summarized 
in Table 1. Five domains were evaluated using 
the ASQ, including communication, gross motor, 
fine motor, problem-solving, and personal-social 
skills. Of the 78 children, 3 to 5 yr old with 
congenital hypothyroidism, 32 patients (41%) had 
elevated ASQ score. The frequency of these five 
impairments is depicted in Figure 1.
Problem-solving skills was the most frequent 
type of developmental impairment among female 
children, while the global motor was the most 
prevalent one among male children. 
Age at diagnosis, initial dose of Levothyroxine (μgr/
kg/d) and mean age at start of T4 supplementation 
age were the three variables that differed 
significantly between children with a normal 
ASQ test and those with an impaired ASQ test. 
Comparison of laboratory and treatment-related 
variables of subjects with normal ASQ score and 
those with elevated ASQ score are explained in 
Tables 2 and 3.
Those treated with initial dose LT4 ≤12 µgr/kg/d 
at diagnosis had a higher ASQ score (impaired) 
compared with those treated with a dose ≥ 12 μgr/
kg/d (P=0.017) (Table 3). In those with normal 
ASQ, confirmation of the diagnosis was established 
at average 17.9 d and commencement of therapy 
with LT4 was at average 20.2 d. Whereas, in the 
group with impaired ASQ it was at average 25.65 
and 26.59 d respectively. Laboratory and treatment-
related variables are explained in Table 2.
No significant differences were found in gender, 
living location, birth length, weight, head 
circumference, parental consanguinity, parental 
education, primary venous TSH and T4 levels, 
and number of annual visits between two groups. 
Apart from initial dose of LT4, there was no 
significant association between the elevated ASQ 
score and mean of serum TSH, T4, and mean dose 
of levothyroxine (μgr/kg/d) for first year and 3 yr 
follow up. 
The association between the type CH (transient 
or permanent) and the development status was 
investigated using the Chi-square Test. There was 
not a significant correlation between type of CH 
and ASQ scores (P=0.74) (Table 4).
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Table 1. Demographic characteristics of included subjects according to ASQ results (n=78).
Variable State
Result of ASQ P-value
Impaired (n=32) Normal (n=46)
Sex
Female 11 23
0.1
Male 21 23
Place of living
Urban 20 36
0.2
Rural 12 10
Parental consanguinity
Yes 8 15
0.3
No 24 31
Maternal education
High school 10 10
0.5Diploma 16 23
Academic 6 13
Paternal education
High school
4 5
0.6
Diploma 18 21
Academic 10 20
Mean maternal age (year) 26.5 (5.0) 27.4 0.37
Mean birth length (cm) 49.2 49.1 0.23
Mean birth weight (gr) 3223.9 3076.6 0.35
Mean birth head circumference (cm) 35.9 36.0 0.89
Table 2. Comparison of laboratory and treatment-related variables of participants with normal and impaired ASQ (n=78). 
Variable
Result of ASQ
P-value
Normal Impaired
Diagnosis age (day) 17.95 25.65 0.002
Initial treatment age (day) 20.21 26.59 0.018
Initial blood TSH (mIU/ml) 38.86 40.42 0.76
Mean TSH for first year (mIU/ml) 4.6 5.31 0.26
Initial blood T4 (μg/dL) 5.60 4.99 0.39
Mean TSH for 3 yr (mIU/ml) 2.56 2.96 0.48
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Table 3. ASQ results according to initial dose of LT4.
Initial 
LT4 dose (μg/kg/d)
ASQ result (Number and %)
N=64
Df
OR
95%CI
P-value
Normal Impaired U L
<12 19 (43.1) 22 (68.8) 1 3.1 8 1.2 0.017
≥12 27 (57.7) 10 (31.2) 2 0 0
Table 4. Association between the types of congenital hypothyroidism (CH) and development status (n=78).
The Type of CH
ASQ results
P-valueImpairment
Number (%)
Normal
Number (%)
Total
Number (%)
Transient 5 (45.5) 6 (54.5) 11 (100)
0.74Permanent 27 (40.3) 40 (59.7) 67 (100)
Total 32 (41) 46 (59) 78 (100)
      
Figure 1. Frequency of impairment of five domains screened by ages & stages questionnaires or ASQ (1. 
communication, 2. fine motor, 3. personal-social, 4. problem-solving, 5. global). 
 
 
 
Figure 1. Frequency of impairment of five domains screened by ages & stages questionnaires or ASQ 
(1. communication, 2. fine motor, 3. personal-social, 4. problem-solving, 5. global).
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Discussion
The early detection and treatment along with 
adequate L-thyroxin dose lead to normal or near-
normal neurocognitive outcomes in children with 
congenital hypothyroidism (17). Despite this, 
several studies have shown subnormal cognitive 
and motor development of timely treated congenital 
hypothyroidism (17-20).
In the present study, ASQ score was subnormal 
in 41% of early treated children with congenital 
hypothyroidism (elevated ASQ score). Problem-
solving and global motor were the most frequent 
types of developmental impairment among female 
and male respectively. This is a surprising and 
unexpected finding. We assume the reason for high 
rate of abnormal ASQ is that ASQ is a developmental 
screening not diagnostic test that can help parents 
check their child’s development and mental 
problem. In the next step, these children should be 
evaluated using standard IQ measurement scores. 
The results of further diagnostic tests may confirm 
or refute our findings. 
The associations between ASQ score and some 
demographic and laboratories’ variables were 
also assessed. We could not find any relation 
between the birth length, birth weight, birth head 
circumference, maternal age at pregnancy, sex, 
place of life, relation of parents, and parents’ 
education. Unlike our findings, parental education 
influenced intellectual development of the children 
with congenital hypothyroidism (21).
In this study, there was no relationship between 
biochemical severity (TSH and T4 levels at 
diagnosis) and ASQ scores. This finding is similar 
to the results of other studies (2, 22). No significant 
association was found between the severity of CH 
and intelligence coefficient (IQ) of patients with 
CH (23).
In contrast to our study, CH severity was correlated 
primarily with motor test results and reduced IQs 
(24, 25). A negative significant correlation was 
reported between initial TSH level and IQ scores 
among Dutch CH patients (26). On the other hand, 
no association was found between mild congenital 
hypothyroidism (TSH levels less than 15 mIU/L) 
and psychomotor development of preschool 
children in Belgium (27).
Similar to other studies (28-31), we could not 
find a significant difference between the two 
groups of impaired and normal ASQ scores in 
terms of the type of hypothyroidism (transient and 
permanent). This implies that adequate amounts 
of thyroid hormones early in life is essential for 
normal neurocognitive development. In contrast, 
transient thyroid dysfunction in the newborn 
was not associated with impaired psychomotor 
development (27).
Based on the evidence of this study, initiation of 
therapy with higher dose of LT4 (12 µgr/kg/d) was 
associated with a more favorable prognosis in ASQ 
score and intellectual development of congenitally 
hypothyroid children suggesting that initial 
L-thyroxin is an important factor for subsequent 
intellectual development of congenitally 
hypothyroid children.
In support of studies (2, 28), we believe that in 
order to achieve a good outcome, treatment of 
congenital hypothyroidism should be started with 
higher dose of LT4 than previously recommended. 
In this study, the mean age of diagnosis and 
treatment initiation was 20 days (these two 
variables were very close in their values because 
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the treatment normally begins after the diagnosis) 
represents that diagnosis and start of treatment in 
CH infants were slightly later than recommended 
time frame of 14 days (3). Confirming previous 
studies (3, 16, 13, 17, 24) we assume that treating 
CH infants before 2 wk of age can give rise to better 
cognitive or motor outcome. Despite this, a study 
of Dutch children with congenital hypothyroidism 
found that advancing commencement of therapy 
from 28 days to 20 days after birth cannot fully 
normalize intellectual performance of affected 
children (32). 
Undoubtedly, our study has several limitations 
that need to be considered. First, we measured the 
cognitive outcome in terms of developmental status 
screening and not in terms of IQ confirmatory. 
Consequently, the question that needs to be 
answered is what number of studied subjects 
had abnormal cognitive and neurodevelopmental 
outcomes using standardized IQ testing. Secondly, 
ASQ score of studied subjects had not been 
compared with healthy control children. Thirdly, 
we did not consider mean time of normalization 
of T4 and TSH and parental socioeconomic status. 
Further studies in this regard are mandatory.
Finally, ASQ score of the relatively small sample 
size limits the study’s statistical power. These 
limitations require further investigation.
In conclusion, ASQ score was subnormal in 41% 
of treated patients with congenital hypothyroidism. 
Early diagnosis, early initiation of treatment, and 
initial L-thyroxin dose are important to optimal 
neurodevelopmental. The initial levothyroxine dose 
should be higher than 12 μg/kg/d. Confirmation 
and start of treatment of CH should be within 
the recommended time of 2 wk. However, the 
developmental status of studied subjects was 
measured using the ASQ screening methods, 
further studies should assess intelligence quotient 
(IQ) using standardized IQ testing.
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